Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lesko

Showing results (181-190 of 231) with videos related to

Pageof 24
Sort By:
Pharmaceutical Research|July 10, 2001
Variability in the bioavailability of phenytoin capsules in males and femalesM C Meyer, A B Straughn, R M Mhatre, et al.
Journal of Surgical Oncology|November 1, 1996
Pharmacokinetics of dacarbazine in the regional perfusion of extremities with melanomaM S Didolkar, A J Jackson, L J Lesko, et al.
Journal of Pharmacokinetics and Pharmacodynamics|April 27, 2020
A clinical population pharmacokinetic/pharmacodynamic model for BIIB059, a monoclonal antibody for the treatment of systemic and cutaneous lupus erythematosusSonja Hartmann, Konstantinos Biliouris, Himanshu Naik, et al.
Journal of Clinical Pharmacology|April 29, 1998
Defining the maximum tolerated dose: investigator, academic, industry and regulatory perspectivesN R Cutler, J J Sramek, D J Greenblatt, et al.
Clinical Pharmacology and Therapeutics|October 3, 2000
In vivo drug-drug interaction studies--a survey of all new molecular entities approved from 1987 to 1997P J Marroum, R S Uppoor, T Parmelee, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 1, 2018
A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humansKonstantinos Biliouris, Ivan Nestorov, Himanshu Naik, et al.
The Journal of Allergy and Clinical Immunology|April 1, 1997
Production of IL-5 and granulocyte-macrophage colony-stimulating factor by naive human mast cells activated by high-affinity IgE receptor ligationR B Bressler, J Lesko, M L Jones, et al.
Journal of Clinical Pharmacology|September 3, 1999
FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labelingB Davit, K Reynolds, R Yuan, et al.
Journal of Clinical Pharmacology|February 24, 2001
Pharmacokinetic/pharmacodynamic modeling in drug research and developmentH Derendorf, L J Lesko, P Chaikin, et al.
Clinical Pharmacology and Therapeutics|August 25, 2016
Identifying clinically relevant sources of variability: The clopidogrel challengeS Samant, X L Jiang, L A Peletier, et al.
Pageof 24

Showing results (181-190 of 231) with videos related to

Sort By:
Pageof 24
Pharmaceutical Research|July 10, 2001
Variability in the bioavailability of phenytoin capsules in males and femalesM C Meyer, A B Straughn, R M Mhatre, et al.
Journal of Surgical Oncology|November 1, 1996
Pharmacokinetics of dacarbazine in the regional perfusion of extremities with melanomaM S Didolkar, A J Jackson, L J Lesko, et al.
Journal of Pharmacokinetics and Pharmacodynamics|April 27, 2020
A clinical population pharmacokinetic/pharmacodynamic model for BIIB059, a monoclonal antibody for the treatment of systemic and cutaneous lupus erythematosusSonja Hartmann, Konstantinos Biliouris, Himanshu Naik, et al.
Journal of Clinical Pharmacology|April 29, 1998
Defining the maximum tolerated dose: investigator, academic, industry and regulatory perspectivesN R Cutler, J J Sramek, D J Greenblatt, et al.
Clinical Pharmacology and Therapeutics|October 3, 2000
In vivo drug-drug interaction studies--a survey of all new molecular entities approved from 1987 to 1997P J Marroum, R S Uppoor, T Parmelee, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 1, 2018
A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humansKonstantinos Biliouris, Ivan Nestorov, Himanshu Naik, et al.
The Journal of Allergy and Clinical Immunology|April 1, 1997
Production of IL-5 and granulocyte-macrophage colony-stimulating factor by naive human mast cells activated by high-affinity IgE receptor ligationR B Bressler, J Lesko, M L Jones, et al.
Journal of Clinical Pharmacology|September 3, 1999
FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labelingB Davit, K Reynolds, R Yuan, et al.
Journal of Clinical Pharmacology|February 24, 2001
Pharmacokinetic/pharmacodynamic modeling in drug research and developmentH Derendorf, L J Lesko, P Chaikin, et al.
Clinical Pharmacology and Therapeutics|August 25, 2016
Identifying clinically relevant sources of variability: The clopidogrel challengeS Samant, X L Jiang, L A Peletier, et al.
Pageof 24